Edition:
United Kingdom

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

38.19USD
8:59pm GMT
Change (% chg)

$0.80 (+2.14%)
Prev Close
$37.39
Open
$37.64
Day's High
$38.28
Day's Low
$37.64
Volume
111,785
Avg. Vol
259,082
52-wk High
$38.74
52-wk Low
$13.51

Chart for

About

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $520.30
Shares Outstanding(Mil.): 22.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients

* ADAMAS ANNOUNCES U.S. COMMERCIAL LAUNCH OF GOCOVRI™ THE FIRST AND ONLY FDA-APPROVED MEDICATION FOR THE TREATMENT OF DYSKINESIA IN PARKINSON’S DISEASE PATIENTS Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04

* Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results

02 Nov 2017

BRIEF-Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals

* Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​ Source text (http://bit.ly/2zY2CVE) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

01 Nov 2017

BRIEF-Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​

* Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​ Source text : (http://bit.ly/2lnW6oI) Further company coverage:

27 Oct 2017

BRIEF-Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI

* FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Adamas appoints Mardi C. Dier to its board of directors

* Adamas appoints Mardi C. Dier to its board of directors Source text for Eikon: Further company coverage:

11 Oct 2017

BRIEF-Adamas Pharmaceuticals says unit entered into amended and restated API supply agreement with Moehs Ibérica

* Adamas Pharmaceuticals says ‍on Oct 4, unit entered into amended and restated API supply agreement with Moehs Ibérica - SEC Filing

06 Oct 2017

BRIEF-Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals‍​

* Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals as of August 29 - SEC filing ‍​ Source text: [http://bit.ly/2xSxczx] Further company coverage:

07 Sep 2017

BRIEF-Adamas announces topline phase 1b data of ADS-4101 for the treatment of partial onset seizures in epilepsy

* Adamas announces topline phase 1b data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy

07 Sep 2017

Adamas Pharma secures approval for Parkinson's dyskinesia drug

The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc's treatment for a side effect caused by a commonly prescribed Parkinson's drug, sending the shares of the drugmaker soaring in after-market trading.

24 Aug 2017

Earnings vs. Estimates